COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

New Funding Opportunity: Biospecimen Core Resource

The purpose of this notice is to notify the community that the National Cancer Institute's (NCI’s) Office of Cancer Clinical Proteomics Research (OCCPR) is seeking sources to establish a Biospecimen Core Resource (BCR), capable of receiving, qualifying, processing, and distributing annotated biospecimens.

A goal of the next phase of NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is to improve our understanding of cancer biology by extending CPTAC’s scientific approach to additional cancer types where unanswered questions remain on their proteogenomic complexity. A component of this goal is the acquisition of high‐quality, clinically annotated, primary, and untreated tumor specimens from patients with specific cancer types. Tissue Source Sites (TSS) will prospectively collect primary, human tumors according to a SOP-driven protocol optimized for proteomics. Complete cases will consist of tumor, blood, and, where possible, non-malignant tissue.